Search results for "lymph"

showing 10 items of 4590 documents

Para-aortic lymphadenectomy in abnormal common iliac bifurcation

2021

A 60-year-old-woman was diagnosed with serous endometrial cancer and on pre-operative CT there was evidence of a higher confluence of the common iliac veins in the inferior vena cava ([Figure 1][1]). Due to the presence of ascites (800 mL) and of a neoplastic ileal nodule at laparoscopy, to avoid

medicine.medical_specialtyretroperitoneal spacelymphatic systemIliac VeinInferior vena cavasurgerysurgical oncologySurgical oncologyblood vesselAscitesHumansMedicineRetroperitoneal spaceLaparoscopymedicine.diagnostic_testbusiness.industryEndometrial cancerObstetrics and GynecologyNodule (medicine)Middle Agedmedicine.diseaseSerous fluidmedicine.anatomical_structureOncologymedicine.veincardiovascular systemLymph Node ExcisionFemaleRadiologymedicine.symptombusiness
researchProduct

Predictors of Central Compartment Involvement in Patients with Positive Lateral Cervical Lymph Nodes According to Clinical and/or Ultrasound Evaluati…

2021

Lymph node neck metastases are frequent in papillary thyroid carcinoma (PTC). Current guidelines state, on a weak level of evidence, that level VI dissection is mandatory in the presence of latero-cervical metastases. The aim of our study is to evaluate predictive factors for the absence of level VI involvement despite the presence of metastases to the lateral cervical stations in PTC. Eighty-eight patients operated for PTC with level II–V metastases were retrospectively enrolled in the study. Demographics, thyroid function, autoimmunity, nodule size and site, cancer variant, multifocality, Bethesda and EU-TIRADS, number of central and lateral lymph nodes removed, number of positive lymph n…

medicine.medical_specialtyskip metastasisendocrine system diseasesmedicine.medical_treatment030230 surgeryArticle03 medical and health sciences0302 clinical medicinecentral compartmentmedicinelateralcervical lymph nodesLymph nodeUnivariate analysisbusiness.industryEU-TIRADSBethesdaRCancerNeck dissectionGeneral Medicinemedicine.diseaseCentral lymphDissectionmedicine.anatomical_structurelateral neck dissection030220 oncology & carcinogenesiscentral neck dissectionpapillary thyroid carcinomaMedicineRadiologyLymphThyroid functionbusinessJournal of clinical medicine
researchProduct

Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell…

2021

The potential role of active CMV infection in promoting acute Graft-versus-Host Disease (aGvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. We further addressed this issue conducting a retrospective, observational, multicenter study of 632 patients subjected to allogeneic peripheral blood HSCT at 20 Spanish centers. Monitoring of CMV DNA load in plasma or whole blood was performed by real-time PCR assays. Cumulative incidence of CMV DNAemia was 48.9% (95% CI, 45%-52.9%), of any grade aGvHD, 45.6; 95% (CI, 41.3%-50.1%), and of grade II-IV aGvHD, 30.7 (95% CI, 24.9%-36.4%). Overall, development of CMV DNAemia at any level resulted in an increa…

medicine.medical_specialtyversus&#8208medicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusGraft vs Host DiseaseDiseaseHematopoietic stem cell transplantationCMV DNAemia030230 surgeryGastroenterologyCMV DNAemia acute graft-versus-host disease allogeneic hematopoietic stem cell transplantation cytomegalovirus (CMV)Cell therapy03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesMedicineHumansCumulative incidenceallogeneic hematopoietic stem cell transplantationWhole bloodRetrospective StudiesTransplantationhost diseasePeripheral Blood Stem Cell Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseaseacute graft&#8208TransplantationHaematopoiesisInfectious Diseasessurgical procedures operativecytomegalovirus (CMV)030211 gastroenterology & hepatologybusinessTransplant infectious disease : an official journal of the Transplantation SocietyREFERENCES
researchProduct

Die Lungentuberkulose – aktuelle radiologische Diagnostik einer alten Krankheit

2000

Inzidenz. Abnehmende Inzidenzen aktiver Tuberkulose in den Industrielandern haben diese Erkrankung aus dem Bewusstsein vieler verdrangt. Dennoch stellt die Tuberkulose weiterhin weltweit die am haufigsten zum Tode fuhrende Infektionskrankheit dar. In den Industrielandern tragen Faktoren wie Einwanderungsbewegungen, zunehmende Verarmung und die Zunahme immunsupprimierter Patienten, insbesondere durch die HIV-Epidemie, dazu bei, dass ein Reservoir fur die Tuberkulose aufrecht erhalten wird. Diagnose. Eine fruhzeitige Diagnose ist wegen der spezifischen Therapiemoglichkeiten entscheidend fur den Krankheitsverlauf; im Falle von multiresistenten Stammen ist sie wichtig zur Verhinderung einer wei…

medicine.medical_specialtyÜbersichtLungeReviewKey words TuberculosisSchlüsselwörter TuberkuloseDiagnostikHumansMedicineRadiology Nuclear Medicine and imagingTuberculomaTuberculin testLungDiagnosticsTuberculosis PulmonaryGynecologyAIDS-Related Opportunistic InfectionsTuberculin Testbusiness.industryChronische InfektionenSputumMycobacterium tuberculosisRadiographyLung diseaseHIV-1Lymph NodesbusinessDer Radiologe
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.

1998

The disappointing clinical results of cancer immunotherapy of the past few decades have not diminished the optimism about the potential of the new generation of immunotherapeutic strategies towards treatment of malignant disease. Tremendous progress has been made over recent years in unveiling the molecular basis of antigen presentation and recognition by cytotoxic T lymphocytes (CTL). The molecular concepts that have emerged from these studies have led to the design of novel anticancer vaccines and CTL-based immunotherapeutics. This review is to highlight the current molecular insights of antigen presentation and CTL recognition/activation, and their impact on the rational design of therap…

medicine.medical_treatmentAntigen presentationMolecular Sequence Datachemical and pharmacologic phenomenaCancer VaccinesImmune systemCancer immunotherapyNeoplasmsDrug DiscoverymedicineCytotoxic T cellAnimalsHumansAmino Acid SequenceGenetics (clinical)Antigen Presentationbusiness.industryImmunotherapyT lymphocyteMolecular medicineCTL*ImmunologyMolecular MedicineImmunotherapybusinessT-Lymphocytes CytotoxicJournal of molecular medicine (Berlin, Germany)
researchProduct

Cytokine expression and antigen-presenting capacity of 4F7 + dendritic cells derived from dermis, spleen, and lymph nodes

1997

We took advantage of the recently generated 4F7 mAb, which recognizes an epitope expressed on dendritic cells (DC) from different tissues, to freshly isolate and positively sort for these cells and to characterize their cytokine pattern and antigen-presenting capacity in comparison with epidermal Langerhans cells (LC). RT-PCR and Northern blot analyses demonstrated constitutive mRNA expression of MIP-1 gamma, MIP-1 alpha, C10, and IL-1 beta in both 4F7+ DC and LC. Lipopolysaccharide (LPS) treatment resulted in the upregulation of mRNA expression of all four cytokines and in a newly detected signal for TNF alpha. Immunoblot analysis showed constitutive secretion of MIP-1 gamma, with LPS trea…

medicine.medical_treatmentAntigen presentationSpleenDermatologyBiologyEpitopeMicemedicineAnimalsRNA MessengerNorthern blotSkinCommon gamma chainAntigen PresentationMice Inbred BALB CDendritic CellsGeneral MedicineDendritic cellMolecular biologymedicine.anatomical_structureCytokineImmunologyMice Inbred CBACytokinesFemaleTumor necrosis factor alphaLymph NodesSpleenArchives of Dermatological Research
researchProduct

Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity

2008

Despite as yet limited clinical effectiveness, dendritic cell (DC)-based immunotherapy remains a promising approach for the treatment of cancer, but requires further improvement in its immunostimulatory effectiveness. Potent anti-tumor immunity often depends on the induction of type 1 (T(H)1) immune responses. Therefore, we combined different DC maturation stimuli that are known to induce T(H)1 immunity [anti-CD40, interleukin (IL)-12, IL-18], with the aim to trigger a T(H)1 driven anti-tumor CTL response. When compared with untreated DC or DC treated with anti-CD40 alone, DC matured with anti-CD40 plus IL-12 and IL-18 expressed significantly more IFN-gamma and IL-12, induced enhanced CD8(+…

medicine.medical_treatmentAntineoplastic AgentsDermatologyCD8-Positive T-LymphocytesModels BiologicalBiochemistryMiceImmune systemAntigens NeoplasmmedicineAnimalsCD40 AntigensAntigen-presenting cellMolecular BiologyMice Inbred BALB Cbusiness.industryInterleukin-18InterleukinDendritic CellsImmunotherapyDendritic cellTh1 CellsInterleukin-12Tumor antigenMice Inbred C57BLImmune SystemImmunologyInterleukin 12ImmunotherapybusinessCD8Experimental Dermatology
researchProduct

Influence of extracellular matrix proteins on the development of cultured human dendritic cells.

1998

The development of dendritic cells (DC) is still only partly understood. Recently established culture systems using CD34+ cells or monocytes as precursor cells for the generation of DC indicate the necessity of pro-inflammatory cytokines for their development. In vivo the contact to other cells or to the proteins of the extracellular matrix might also be essential for their development. In our experiments we used granulocyte-macrophage colony-stimulating factor- and IL-4-treated human monocytes as precursor cells to investigate the interaction of DC at different maturation stages with the matrix proteins fibronectin, collagen type I and collagen type IV. We demonstrate a strong beta1-integr…

medicine.medical_treatmentCellular differentiationImmunologyCD34Cell CommunicationMatrix (biology)BiologyMonocytesExtracellular matrixPrecursor cellmedicineCell AdhesionImmunology and AllergyHumansCells CulturedExtracellular Matrix ProteinsTumor Necrosis Factor-alphaIntegrin beta1Cell DifferentiationDendritic cellDendritic CellsCell biologyFibronectinsUp-RegulationFibronectinCytokineAntigens Surfacebiology.proteinCollagenLymphocyte Culture Test MixedEuropean journal of immunology
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct